An intra-islet incretin system has been recently suggested to operate through modulation of the expression and activity of proconvertase 1/3 and 2 (PC1/3, PC2) in pancreatic alpha-cell accounting for local release of GLP-1. Little is known, whether this alpha-cell activity can be affected by the metabolic alterations occurring in type 2 diabetes, such as hyperglycemia, hyperlipidemia or hyperglucagonemia.AlphaTC1/6 cells from a mice pancreatic cell line were incubated in the presence of two glucose (G) concentration (5.5 and 16.7 mM) for 16 h with or without free fatty acid, IL6 or glucagon. GLP-1 secretion was measured by ELISA and expression of PC1/3 and PC2 by RT-PCR and western blot; cell viability was determined by MTT method, Reactive...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Pancreatic α-cells are the major source of glucagon, a hormone that counteracts the hypoglycemic act...
Objective: Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diab...
<div><p>Background and aims</p><p>An intra-islet incretin system has been recently suggested to oper...
Incretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological i...
Glucagon-like peptide-1 (GLP-1) has received much attention as a novel diabetes therapeutic due to i...
T2D is a bihormonal disorder characterised by hypoinsulinaemia and hyperglucagonaemia. The incretin...
Incretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological i...
Aims/Hypothesis: Incretin therapies, which are used to treat diabetic patients, cause a chronic supr...
AIMS/HYPOTHESIS: Glucagon-like peptide 1 (GLP-1) is a major incretin, mainly produced by the intesti...
Pancreatic α cells may process proglucagon not only to glucagon but also to glucagon-like peptide-1 ...
A major, yet poorly understood, feature of type 2 diabetes is the excessive hepatic glucose producti...
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone expressed from intestinal L cells ...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Hyperproinsulinemia has gained increasing attention in the development of type 2 diabetes. Clinical ...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Pancreatic α-cells are the major source of glucagon, a hormone that counteracts the hypoglycemic act...
Objective: Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diab...
<div><p>Background and aims</p><p>An intra-islet incretin system has been recently suggested to oper...
Incretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological i...
Glucagon-like peptide-1 (GLP-1) has received much attention as a novel diabetes therapeutic due to i...
T2D is a bihormonal disorder characterised by hypoinsulinaemia and hyperglucagonaemia. The incretin...
Incretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological i...
Aims/Hypothesis: Incretin therapies, which are used to treat diabetic patients, cause a chronic supr...
AIMS/HYPOTHESIS: Glucagon-like peptide 1 (GLP-1) is a major incretin, mainly produced by the intesti...
Pancreatic α cells may process proglucagon not only to glucagon but also to glucagon-like peptide-1 ...
A major, yet poorly understood, feature of type 2 diabetes is the excessive hepatic glucose producti...
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone expressed from intestinal L cells ...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Hyperproinsulinemia has gained increasing attention in the development of type 2 diabetes. Clinical ...
Pancreatic β cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by e...
Pancreatic α-cells are the major source of glucagon, a hormone that counteracts the hypoglycemic act...
Objective: Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diab...